Abstract:The persistence of increased excitability and spontaneous activity in injured peripheral neurons is imperative for the development and persistence of many forms of neuropathic pain. This aberrant activity involves increased activity and/or expression of voltage-gated Na + and Ca 2+ channels and hyperpolarization activated cyclic nucleotide gated (HCN) channels as well as decreased function of K + channels. Because they display limited central side effects, peripherally restricted Na + and Ca 2+ channel blockers and K + channel activators offer potential therapeutic approaches to pain management. This review outlines the current status and future therapeutic promise of peripherally acting channel modulators. Selective blockers of Na v 1.3, Na v 1.7, Na v 1.8, Ca v 3.2, and HCN2 and activators of K v 7.2 abrogate signs of neuropathic pain in animal models. Unfortunately, their performance in the clinic has been disappointing; some substances fail to meet therapeutic end points whereas others produce dose-limiting side effects. Despite this, peripheral voltage-gated cation channels retain their promise as therapeutic targets. The way forward may include (i) further structural refinement of K + channel activators such as retigabine and ASP0819 to improve selectivity and limit toxicity; use or modification of Na + channel blockers such as vixotrigine, PF-05089771, A803467, PF-01247324, VX-150 or arachnid toxins such as Tap1a; the use of Ca 2+ channel blockers such as TTA-P2, TTA-A2, Z 944, ACT709478, and CNCB-2; (ii) improving methods for assessing “pain” as opposed to nociception in rodent models; (iii) recognizing sex differences in pain etiology; (iv) tailoring of therapeutic approaches to meet the symptoms and etiology of pain in individual patients via quantitative sensory testing and other personalized medicine approaches; (v) targeting genetic and biochemical mechanisms controlling channel expression using anti-NGF antibodies such as tanezumab or re-purposed drugs such as vorinostat, a histone methyltransferase inhibitor used in the management of T-cell lymphoma, or cercosporamide a MNK 1/2 inhibitor used in treatment of rheumatoid arthritis; (vi) combination therapy using drugs that are selective for different channel types or regulatory processes; (vii) directing preclinical validation work toward the use of human or human-derived tissue samples; and (viii) application of molecular biological approaches such as clustered regularly interspaced short palindromic repeats (CRISPR) technology.

Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field

Targeting TRP channels for pain relief: A review of current evidence from bench to bedside

Transient receptor potential vanilloid 1 as a therapeutic target in analgesia

TRPV1-Targeted Drugs in Development for Human Pain Conditions

Current insights and therapeutic strategies for targeting TRPV1 in neuropathic pain management

Progress in the development of TRPV1 small-molecule antagonists: Novel Strategies for pain management

Pharmacological agents targeting transient receptor potential (TRP) channels in neuropathic pain: Preclinical and clinical status

TRPV1 Channels in the Central Nervous System as Drug Targets

Peripheral Voltage-Gated Cation Channels in Neuropathic Pain and Their Potential as Therapeutic Targets

Dual Kv7.2/3-TRPV1 modulators inhibit nociceptor hyperexcitability and alleviate pain without target-related side effects

Canonical Transient Receptor Potential (TRPC) Channels in Nociception and Pathological Pain

The pharmacology of TRP channels

The Functional Regulation of TRPV1 and Its Role in Pain Sensitization.

Moving towards Supraspinal TRPV1 Receptors for Chronic Pain Relief

Role of TRPM Channels in Pain States

Targeting TRPV4 Channels for Cancer Pain Relief

A Novel Approach to Pain Therapy: Development of Transient Receptor Potential Vanilloid 1 Antagonists

Receptor and Molecular Targets for the Development of Novel Opioid and Non-Opioid Analgesic Therapies

TRPA1 as a drug target--promise and challenges.

The TRPC5 receptor as pharmacological target for pain and metabolic disease

Contribution of natural products to the discovery of the transient receptor potential (TRP) channels family and their functions